Alternative titles; symbols
Shen et al. (1995) cloned a putative dominant-acting 'nude' mouse prostatic carcinoma tumor-inducing gene that is expressed in patient-derived prostatic carcinomas but not in benign prostatic hypertrophy or normal prostate tissue. The gene was detected by cotransfecting human prostate carcinoma DNA into CREF-Trans 6 cells, inducing tumors in 'nude' mice, and isolating genes displaying increased expression in tumor-derived cells by using differential RNA display. Sequence analysis indicated that the gene (which they called PTI1 for prostatic carcinoma tumor-inducing gene-1) contains a 630-bp 5-prime sequence and a 3-prime sequence homologous to a truncated and mutated form of human elongation factor 1-alpha subunit (EEF1A1; 130590). In vitro translation demonstrated that the PTI1 cDNA encodes a protein of approximately 46 kD. Northern blots identified RNA transcripts in human carcinoma cell lines derived from prostate, lung, breast, and colon. In contrast, PTI1 RNA was not detected in human melanoma, neuroblastoma, osteosarcoma, normal cerebellum, or glioblastoma multiforme cell lines.
Scott (2009) concluded that the PTI1 gene identified by Shen et al. (1995) was likely a cloning artifact.
The EEF1A1 gene (130590) has also been called prostate tumor-induced protein-1 and given the designation PTI1.
Scott, A. F. Personal Communication. Baltimore, Md. 7/6/2009.
Shen, R., Su, Z.-Z., Olsson, C. A., Fisher, P. B. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc. Nat. Acad. Sci. 92: 6778-6782, 1995. [PubMed: 7542776] [Full Text: https://doi.org/10.1073/pnas.92.15.6778]